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Background: Endogenous sex hormones are well-established risk factors for breast cancer; the contribution of specific oestrogen
metabolites (EMs) and/or ratios of specific EMs is less clear. We have previously identified a CYP3A7*1C allele that is associated
with lower urinary oestrone (E1) levels in premenopausal women. The purpose of this analysis was to determine whether this allele
was associated with specific pathway EMs.
Methods:We measured successfully 12 EMs in mid-follicular phase urine samples from 30 CYP3A7*1C carriers and 30 non-carriers
using HPLC-MS/MS.
Results: In addition to having lower urinary E1 levels, CYP3A7*1C carriers had significantly lower levels of four of the
2-hydroxylation pathway EMs that we measured (2-hydroxyestrone, P¼ 1.1 10 12; 2-hydroxyestradiol, P¼ 2.7 10 7;
2-methoxyestrone, P¼ 1.9 10 12; and 2-methoxyestradiol, P¼ 0.0009). By contrast, 16a-hydroxylation pathway EMs were
slightly higher in carriers and significantly so for 17-epiestriol (P¼ 0.002).
Conclusions: The CYP3A7*1C allele is associated with a lower urinary E1 levels, a more pronounced reduction in 2-hydroxylation
pathway EMs and a lower ratio of 2-hydroxylation:16a-hydroxylation EMs in premenopausal women. To further characterise the
association between parent oestrogens, EMs and subsequent risk of breast cancer, characterisation of additional genetic variants
that influence oestrogen metabolism and large prospective studies of a broad spectrum of EMs will be required.
Endogenous sex hormones are well-established risk factors for breast
cancer. Pooled analyses of data from prospective studies have
estimated that a doubling of circulating estradiol (E2), free E2 or E1 is
associated with a 20–30% or 30–50% increase in breast cancer risk in
pre- and postmenopausal women, respectively (Key et al, 2002,
2013). The contribution of specific oestrogen metabolites (EMs) to
breast cancer risk is less clear. Briefly, interconversion between the
parent oestrogens, E2 and E1 occurs by reversible oxidation at the
17a-position of the steroid ring; conversion of parent oestrogens to
EMs is by irreversible hydroxylation at the 2-, 4- or 16-positions
(Figure 1; Badawi et al, 2001; Tsuchiya et al, 2005; Samavat and
Kurzer, 2015). A recent review, summarising evidence from four
prospective studies of oestrogen metabolism and breast cancer
risk concluded that there was consistent evidence that enhanced
2-hydroxylation was associated with a reduction in risk of breast
cancer that was independent of the strong positive associations of
unconjugated parent oestrogens (E2 and E1) with breast cancer risk
(Ziegler et al, 2015).
In an analysis of single-nucleotide polymorphisms (SNPs)
tagging genes that are involved in oestrogen synthesis and
metabolism, we identified one SNP, rs10273424, which was
associated with a 22% reduction in levels of urinary E1 glucuronide
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(E1G) in premenopausal women (Johnson et al, 2012). rs10273424
maps to the cytochrome P450 3A (CYP3A) gene cluster at 7q22.1;
the CYP3A genes (CYP3A5, CYP3A7 and CYP3A4) encode
enzymes that catalyse the oxidative metabolism of a wide range
of exogenous and endogenous substrates including parent oestro-
gens (E1 and E2; Figure 1). The metabolic capacity of the CYP3A
enzymes differ, depending on the substrate (Williams et al, 2002);
with respect to oestrogen metabolism specifically, 2-hydroxylation
of E1 to 2-OHE1 is catalysed by CYP3A4, 4-hydroxylation to 4-
OHE1 is catalysed by CYP3A4 and CYP3A5 and 16a-hydroxyla-
tion to 16a-OHE1 is catalysed by CYP3A4, CYP3A5 and CYP3A7
(Figure 1; Badawi et al, 2001; Lee et al, 2003; Tsuchiya et al, 2005).
Fine-mapping of the 7q22.1 association signal for urinary E1G
levels implicated the CYP3A7*1C allele as the causal allele (Johnson
et al, 2016). This allele, which comprises seven highly correlated
single base changes mapping to the CYP3A7 promoter, results in
expression of the fetal CYP3A7 gene in adult carriers of the
CYP3A7*1C allele (Gonzalez, 1988; Kuehl et al, 2001; Burk et al,
2002).
The purpose of this current analysis was to determine whether,
in addition to the association between CYP3A7*1C carrier status
and lower urinary E1G levels, the CYP3A7*1C allele was associated
with a reduction in levels of specific pathway EMs.
MATERIALS AND METHODS
Study population. The study population from which the women
we included in this analysis were drawn has been described
previously (Johnson et al, 2012). Briefly, they comprised 729
premenopausal women who were first-degree relatives and friends
of breast cancer cases participating in the British Breast Cancer
study (Johnson et al, 2005) or participants in the intervention arm
of a trial of annual mammographic screening in young women
conducted in Britain (Mammography Oestrogens and Growth
Factors Study; Walker et al, 2009). To be eligible, women had to be
having regular menstrual cycles, not using hormone replacement
therapy or oral contraceptives and not to have been diagnosed with
breast cancer at recruitment to the study. All women were of
self-reported White British ancestry. To be included in the original
analysis and this subsequent analysis, women had to have provided
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Figure 1. Steroid hormone synthesis and endogenous oestrogen metabolism in humans. The 14 oestrogen metabolites (EMs) formed by
hydroxylation of parent oestrogens (E1 and E2), at the 2-, 4- and 16a-positions of the carbon ring that were measured are shown within the red box.
Enzymes (cytochrome P450 (CYPs) and catechol O-methyltransferase (COMT)) involved in oestrogen metabolism are in red. E1G, measured in our
previous analysis (Johnson et al, 2012), is an E1 conjugate present in urine. The E1 measured in this analysis (after hydrolysis of glucuronide and
sulphate conjugates in the first step of the LC-MS/MS protocol) is highly correlated with E1G (Spearman’s correlation, r¼ 0.70, Po0.0001).
Abbreviations: E1¼oestrone; E2¼estradiol; 2-OHE1¼ 2-hydroxyestrone; 2-OHE2¼ 2-hydroxyestradiol; 2-MeOE1¼ 2-methoxyestrone;
2-MeOE2¼ 2-methoxyestradiol; 3-MeoE1¼ 2-hydroxyestrone-3-methyl ether; 4-OHE1¼4-hydroxyestrone; 4-MeOE1¼4-methoxyestrone;
4-MeOE2¼ 4-methoxyestradiol; 16a-OHE1¼ 16a-hydroxyestrone; E3¼estriol; 16-KetoE2¼16-ketoestradiol; 17-epiE3¼ 17-epiestriol and
17b-HSD¼17b-hydroxysteroid.
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serial urine samples (six follicular phase and one luteal phase), at
pre-specified days of their menstrual cycle for measurement of
creatinine adjusted urinary E1G using an in-house enzyme-linked
immunosorbent assay (Johnson et al, 2012). To maximise the
statistical efficiency of this analysis of the CYP3A7*1C allele, which
has a minor allele frequency (MAF) of just 4% in Northern
European populations (Johnson et al, 2016), we selected 60 women
on the basis of genotype; a random sample of 30 CYP3A7*1C
carriers and 30 CYP3A7*1C non-carriers. We further selected the
two periovulatory samples (samples three and four of the six
sequential follicular phase samples) on the basis that oestrogen
levels would be at their peak in these samples and this would
maximise any differences in levels between CYP3A7*1C carriers
and non-carriers. To minimise random variation, we used the
average of these two sequential samples as our outcome variable.
Ethics. The study was conducted in accordance with the tenets of
the Declaration of Helsinki and all participants provided written
informed consent.
Genotyping. Genotyping of the tag SNP rs45467892, which is
perfectly correlated with the CYP3A7*1C allele, has been described
previously (Johnson et al, 2016). Briefly, genotyping was by
Taqman (Life Technologies, Paisley, UK). The call rate was 96.9%
and concordance between duplicate samples was 100%.
HPLC-MS/MS analysis. LC-MS/MS analysis was carried out for
14 EMs using the method of (Xu et al, 2005, 2007). We were
unable to measure one of the 15 EMs measured by (Xu et al, 2005,
2007) (16-Epiestriol), as there was no commercially available
standard for this EM.
Briefly, two aliquots of frozen urine per woman were sent to the
Mass Spectroscopy Facility for Quantitative Analysis, Faculty of
Natural Science, Imperial College, London, for analysis. Hydrolysis
of glucuronide and sulphate-conjugated EMs to form free EMs was
carried out by mixing 500 ml of freshly thawed urine with 20 ml of
internal standards (comprising 2 ng of each of five deuterium-
labelled oestrogen metabolites (d-EMs); 17b-estradiol-d4, estriol-
d3, 2-hydroxy-17b-estradiol-d5, 2-methoxy-17bestradiol-d5 and
16-epiestriol-d3; Qmx Laboratories Ltd, Dunmow, UK) and 500 ml
of freshly prepared enzymatic hydrolysis buffer (100ml of
b-glucuronidase from Helix pomatia (Type H-2; Sigma-Aldrich,
St Louis, MO, USA) in 10ml 0.15 M sodium acetate buffer, pH 4.6
containing 2mg of ascorbic acid). Samples were incubated at 37 1C
overnight before extraction with dichloromethane and dansyl
chloride dervitazation. The final derivatised samples (200 ml) were
transferred to HPLC vials. Urine samples were randomly allocated
to one of six analytical batches. Each batch contained 1 matrix
blank, 1 matrix blank spiked with internal standards, 8-point
calibration standards, 3 quality control (QC) samples and 20 urine
samples. QC samples were prepared using charcoal stripped
human urine (Golden West Biological Inc., Temecula, CA, USA)
with no detectable levels of oestrogen metabolites, spiked with all
14 EMs at a concentration of 2 ngml 1.
Samples (10 ml) were then analysed by HPLC-electrospray
ionisation/MS-MS using an Agilent 1100 HPLC coupled to an
SCIEX QTRAP 6500 mass spectrometer (AB Sciex LLC, Framing-
ham, MA, USA) running in multiple reaction monitoring (MRM)
mode. Chromatographic separation was carried out on a
Phenomenex Synergi Hydro-RP 4 mm 150mm 2.0mm col-
umn, at 40 1C. The solvent gradient used was 35%A (99.8% H2O:
0.2% CHOOH) to 85%B (99.8% MeOH: 0.2% CHOOH) over
60min. Solvent B was held at 85% for 4min, then the solvent
returned to 35% A for 10min equilibration before the next
injection. The solvent flow rate was 250 ml min 1. The ESI source
(type: Ion Drive Turbo V) parameters were set to the following:
TEM 500 1C, Curtain Gas 45 psi, GS1 50 psi, GS2 60 psi and MS
parameters were CAD gas Medium, DP 80, EP 10, CE 45 and CXP
5. A scheduled detection method was used and the MRM detection
window was 120 s with a target scan time of 1 s. Transitions and
retention times are listed in Supplementary Table 1.
Analyst 1.6.2 software (AB Sciex LLC) was used for quantifica-
tion of the EMs. Peak quantifications were carried out using d-EM
internal standards and constructing matrix matched (charcoal
stripped human urine) eight-point calibration curves for each of
the six analytical batches. The calibration curves were evaluated by
plotting the peak area ratios of dansyl-EM/d-dansyl-EM against
concentration (ngml 1) of EMs in the standard and using linear
regression with 1/X weighting to fit the data. Using this linear
function, the amounts of EMs in the urine sample were
interpolated.
The intra- and inter-batch coefficients of variation (CVs),
evaluated from three QC samples per analytical batch, in six
independent consecutive batches (N¼ 18 QC samples) ranged
from 6% to 10% (intra-batch CV) and 6% to 14% (inter-batch CV;
Supplementary Table 2). The two highest inter-batch CVs were
for 4-methoxyestrone (14%) and 4-methoxyestradiol (13%),
the two oestrogen metabolites that had the lowest concentrations
and which were subsequently excluded from the analysis.
The LLOQ was estimated as 80 pgml 1, where the intra- and
inter-batch precision of all the EMs were consistently o10% and
the intra- and inter batch accuracies were between 97 and 105%.
The LOD for the entire assay (all 14 EMs) was estimated to
be 8 pgml 1.
Statistical analysis. EMs were converted from ngml 1 of urine to
pgmg 1 creatinine using the molecular weight of the unconju-
gated form of each of the EMs and the amount of creatinine
(measured in mgml 1) for each of the samples. This allowed us to
create pathway variables as described by Faupel-Badger et al
(2010). Where both of the two samples per woman were measured
successfully, we used the mean of the two measurements; where
one of two measurements from a woman was missing, we used the
one available measurement; where both measurements were
missing, we excluded the woman from the analysis of this EM.
For the majority of EMs, there were no missing values. For
four EMs (2-hydroxyestrone (2-OHE1), 2-methoxyestradiol
(2-MeOE2), 2-hydroxyestrone-3-methyl ether (3-MeOE1) and
16-ketoestradiol (16-ketoE2)), there were o10% missing values
(Supplementary Table 3). For two EMs (4-methoxyestrone
(4-MeOE1) and 4-methoxyestradiol (4-MeOE2)), levels were
undetectable in the majority of samples (92 (76.7%) and 107
(89.2%) for 4-MeOE1 and 4-MeOE2, respectively). These two EMs
were excluded from further analysis. For the 12 EMs that we were
able to measure, we estimated the within-woman variation based
on the two sequential samples per woman; intra-class correlation
coefficients for individual EMs and grouped EMs are shown in
Supplementary Table 4.
For individual and pathway EMs, we calculated geometric
means and 95% confidence intervals (CIs) on the natural logarithm
scale and exponentiated the values back to the original scale. Linear
regression models of the loge-transformed EMs were used to
estimate per cent differences between CYP3A7*1C carriers and
non-carriers for individual and pathway EMs. We carried out
unadjusted analyses and analyses that were adjusted for measure-
ment batch (1–6), body mass index (BMI; quartiles), age at first
full-term pregnancy (quartiles) and parity (0, 1–2, 42). Adjust-
ment for these covariates did not alter effect sizes substantially and,
therefore, unadjusted results are presented. We used t-tests of the
linear regression coefficient to estimate P-values. We applied a
Bonferroni correction to establish a statistical significance level of
Po0.003, based on our measuring of 14 individual EMs and
5 grouped EMs. Statistical analyses were carried out using
R (version 3.2.3; http://cran.r-project.org). All reported P-values
are two-sided.
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RESULTS
Characteristics of the 60 women who were included in this analysis
are presented in Table 1; there were no differences between
CYP3A7*1C carriers and non-carriers. Levels of EMs in
CYP3A7*1C carriers and non-carriers are shown in Figure 2 (full
details of individual EMs, grouped EMs and ratios of EMs are
in Supplementary Table 3). The predominant oestrogen/EMs
were estriol (E3), E1 and 2-hydroxyestrone (2-OHE1) with
geometric mean concentrations in non-carriers of 63.6, 28.6 and
21.8 pmolmg 1 creatinine, respectively. The least abundant
EMs were the methylated 2-catechol EMs, 2-methoxyestradiol
(2-MeOE2) and 2-Hydroxyestrone-3-methyl ether (3-MeOE1) and
17-Epiestriol (17-epiE3) with geometric mean concentrations
in non-carriers of 0.67, 0.74 and 0.31 pmolmg 1 creatinine,
respectively. Levels of the methylated 4-catechol EMs, 4-methox-
yestrone (4-MeOE1) and 4-methoxyestradiol (4-MeOE2) were
below the limits of detection in 92 (76.7%) and 107 (89.2%) of the
120 samples that we assayed.
Comparing CYP3A7*1C carriers with non-carriers, levels of the
parent oestrogen E1 were 45.3% lower in CYP3A7*1C carriers
(P¼ 0.0005, Table 2). For the two catechol EMs (2-OHE1 and
2-OHE2) and the methylated two catechol EMs (2-MeOE1 and
2-MeOE2), the reduction in urinary levels was more extreme;
compared with non-carriers, levels in CYP3A7*1C carriers were
 78.3% (P¼ 1.1 10 12),  67.9% (P¼ 2.7 10 7),  81.2%
(P¼ 1.9 10 12) and  62.8% (P¼ 0.0009) for 2-OHE1, 2-OHE2,
2-MeOE1 and 2-MeOE2, respectively (Table 2). By contrast, levels
of the 16-pathway EMs were slightly higher in CYP3A7*1C
carriers, that is, þ 25.5% (P¼ 0.11), þ 91.6% (P¼ 0.007) and
þ 160.1% (P¼ 0.002) higher for E3, 16a-hydroxyestrone (16a-
OHE1) and 17-epiE3, respectively (Table 2). Adjusting for
measurement batch, BMI, age at first full-term pregnancy and
parity did not alter these results substantially (Supplementary
Table 5).
EMs from the three different oestrogen metabolism pathways
(2-hydroxylation, 4-hydroxylation and 16a-hydroxylation) have
been associated with different oestrogenic and genotoxic properties
(Faupel-Badger et al, 2010; Ziegler et al, 2015) with a high
2-hydroxylation:16a-hydroxylation pathway ratio, generally being
considered to be associated with a reduction in breast cancer
risk. Comparing CYP3A7*1C carriers with non-carriers, the
2-OHE1:16a-OHE1 ratio in carriers (0.39, 95% CI: 0.26–0.57)
was significantly lower than the ratio in non-carriers (3.86, 95% CI:
2.53–5.89; P¼ 1.0 10 11; Supplementary Table 3). Similarly,
combining all 2-hydroxylation pathway and 16a-hydroxylation
pathway metabolites, the ratio in CYP3A7*1C carriers (0.10, 95%
CI: 0.07–0.13) was much lower than the ratio in non-carriers (0.51,
95% CI: 0.38–0.67; P¼ 1.7 10 9; Supplementary Table 3).
DISCUSSION
To our knowledge, comprehensive data on urinary EMs in
premenopausal women, measured using LC-MS, have been
previously reported in three studies (Eliassen et al, 2009, 2012;
Faupel-Badger et al, 2010; Maskarinec et al, 2012). The first of
these was the Nurses’ Health Study II, a prospective study of North
American registered nurses aged 25–42 years at recruitment
(Eliassen et al, 2009, 2012). The second was a population-based
study of incident breast cancer among women of Asian ancestry
living in California and Hawaii (Faupel-Badger et al, 2010) and the
third was a randomised trial of the effect of consuming soy foods
on hormonal outcomes, conducted in women of Caucasian, Native
Hawaiian and Asian ancestry, and living in Hawaii (Maskarinec
et al, 2012).
Comparing absolute levels of EMs in our study with those
reported by these other studies is not straightforward. Levels of
individual EMs and all EMs combined may differ between
ethnicities (Maskarinec et al, 2012) and women from several
different ethnicities have been included in the reports to date
(Asian, Faupel-Badger et al (2010); African-American, Asian,
Hispanic and Caucasian, Eliassen et al (2012); Caucasian, Native
Hawaiian and Asian, Maskarinec et al (2012)). In addition, the 30
non-carriers that we analysed may not be representative of the
general British population, as they were selected on genotype (with
a MAF of 4%, we would expect 2.2 CYP3A7*1C carriers in a
population-based sample of 30 women) and 6 (20%) were first-
degree relatives of breast cancer cases, suggesting that they may be
at higher risk than the general population. Our analysis is based on
the average of two periovulatory samples, Faupel-Badger et al
(2010) analysed both non-luteal phase and luteal phase samples,
Table 1. Characteristics of the 30 CYP3A7*1C carriers and 30
CYP3A7*1C non-carriers included in this analysis
CYP3A7*1C
non-carriers
CYP3A7*1C
carriers
P-value
Age at urine collection 44.1 (16–53) 45.5 (27–50) 0.38
BMI at urine collection 24.0 (19.2–39.9) 25.5 (18.3–39.0) 0.64
Parity
Nulliparous 10 (33.3) 6 (20.0)
1–2 Children 17 (56.7) 15 (50.0)
42 Children 3 (10.0) 9 (30.0) 0.13
Age at first full-term
pregnancya
26.3 (20–31) 27.2 (17–32) 0.39
Abbreviation: BMI¼body mass index.
aIn parous women. For quantitative traits (age at urine collection, BMI at urine collection
and age at first full-term pregnancy), means and ranges are presented. For parity, the
number and percentage of women in each category is shown. For quantitative traits,
P-values were from t-tests; for parity, the P-value was from a Fisher’s exact test.
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Figure 2. Geometric mean levels (pmolmg 1 creatinine) of 12 EMs
that we measured in urine samples from 60 premenopausal women;
30 carriers of the CYP3A7*1C allele (light grey) and 30 non-carriers
(dark grey). Estimates are the average of two samples per woman,
taken on sequential days, calculated to be at or around ovulation based
on the woman’s usual menstrual cycle length. Error bars represent s.e.
Levels of two of the 4-hydroxylation pathway EMs (4-MeOE1 and
4-MeOE2) were below detection in 92 (4-MeOE1) and 107 (4-MeOE2) of
the samples analysed. These two EMs were, therefore, excluded.
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whereas the studies reported by Eliassen et al (2009, 2012) and
Maskarinec et al (2012) focussed on luteal phase samples. There is,
however, no evidence that the 2-OHE1:16a-OHE1 ratio differs
according to the phase of the menstrual cycle (Faupel-Badger et al,
2010). Comparing this ratio across studies, the 2-OHE1:16a-OHE1
ratio in our non-carriers (3.9) was similar to the 2-OHE1:16a-
OHE1 ratios reported by Faupel-Badger et al (2010) (2.2 and 2.1 in
luteal phase and non-luteal phase samples, respectively) and by
Eliassen et al (2012) (4.35) but somewhat lower than the ratios
reported by Maskarinec et al (2012) (8.4 and 13.0 in Asian and
non-Asians, respectively).
We have previously demonstrated that the CYP3A7*1C allele is
associated with lower levels of urinary E1G (Johnson et al, 2016). Here
we have demonstrated that CYP3A7*1C carriers have a more
pronounced reduction in 2-hydroxylation pathway EMs, increased
16a-hydroxylation pathway EMs and markedly reduced two-hydro-
xylation pathway:16a-hydroxylation pathway ratios as measured by
the 2-OHE1:16a-OHE1 ratio (0.39 in CYP3A7*1C carriers compared
with population estimates of 2.1–13.0) or all 2- and 16a-pathway
metabolites combined (0.10 in CYP3A7*1C carriers compared with
population estimates of 0.90 or 0.96 (Eliassen et al, 2009, 2012)).
Our data are consistent with expression of the foetal CYP3A7 gene in
adult carriers of the CYP3A7*1C allele resulting in (i) a modest
reduction in levels of the parent oestrogen E1 and (ii) a specific bias
towards 16a-hydroxylation (which can be catalysed by CYP3A7)
over 2- or 4- hydroxylation (which are not catalysed by CYP3A7
(Lee et al, 2003)).
In their recent review of oestrogen metabolism and breast
cancer, Ziegler et al (2015) concluded that the combined evidence
from prospective studies using LC-MS to measure EMs in pre-
diagnostic serum, plasma and urine was consistent with the
hypothesis that enhanced 2-hydroxylation is associated with
reduced risk of breast cancer. They further concluded that the
inverse association with enhanced 2-hydroxylation (specifically 2-
hydroxylation:16a-hydroxylation and 2-hydroxylation:parent oes-
trogens ratios) was independent of the strong positive associations
between unconjugated E2 and E1 with postmenopausal breast
cancer risk (Ziegler et al, 2015). Our analysis supports these
conclusions if we assume that breast cancer risk in carriers of the
CYP3A7*1C allele is influenced by two components with opposite
effects. Based on the combined evidence of prospective studies of
premenopausal hormone levels and breast cancer risk, lifetime
lower levels of E1 and E2 of B45% and 27% in carriers of the
CYP3A7*1C allele would be predicted to result in a substantial
reduction in risk for these individuals. By contrast, an unfavourable
(reduced) 2-hydroxylation:16a-hydroxylation ratio would be
expected to increase risk. Our previous analyses demonstrate that
the reduction in breast cancer risk for carriers of the rare allele of
rs10235235 (which is correlated with the CYP3A7*1C allele
r2¼ 0.25, D’¼ 1.0) is very modest (heterozygote OR¼ 0.98,
P¼ 0.2; homozygote OR¼ 0.80, P¼ 0.004; Johnson et al, 2014)
consistent with an unfavourable (reduced) 2-hydroxylation:16a-
hydroxylation counteracting a potentially more substantial bene-
ficial effect of lower levels of parent oestrogens.
Table 2. Percentage difference (95% CI) in urinary EM levels comparing CYP3A7*1C carriers with non-carriers
Grouped EM Individual EM % Difference in EMa,b (95% CI) P-value
Total EMs  15.1 (32.7, 7.0) 0.16
Parent EMs  41.0 (57.2,  18.5) 0.002
Oestrone  45.3 (60.6,  24.1) 0.0005
Estradiol  26.7 (47.5, 2.2) 0.07
Catechol EMs  71.0 (80.1,  57.9) 1.2108
2-Catechol EMs  76.1 (83.0,  66.6) 8.4 10 12
2-Hydroxyestronec  78.3 (84.5,  69.6) 1.1 10 12
2- Hydroxyestradiol  67.9 (78.3,  52.6) 2.7107
4-Catechol EMs
4-Hydroxyestrone  51.8 (72.9,  14.2) 0.01
Methylated catechol EM
Methylated 2-catechol EM  73.5 (81.2,  62.7) 1.9 10 10
2-Methoxyestrone  81.2 (87.1,  72.6) 1.9 10 12
2-Methoxyestradiolc  62.8 (78.9,  34.7) 0.0009
2-Hydroxyestrone-3-methyl etherc  21.9 (50.3, 22.6) 0.28
Methylated 4-catechol EMs
4-Methoxyestrone NA NA
4-Methoxyestradiol NA NA
2-Hydroxylation pathway EMs  74.9 (81.6,  65.8) 1.6 10 12
4-Hydroxylation pathway EMs  51.8 (72.9,  14.2) 0.01
16-Hydroxylation pathway EMs 34.7 (1.6, 78.5) 0.04
16a-Hydroxyestrone 91.6 (20.2, 205.1) 0.007
17-Epiestriol 160.1 (46.0, 363.4) 0.002
Estriol 25.5 (5.1, 66.0) 0.11
16-Ketoestradiolc 62.4 (8.7, 142.7) 0.02
Abbreviations: CI¼ confidence interval; EM¼oestrogen metabolite; NA¼not available.
aUnadjusted analysis.
bA negative difference may be interpreted as lower levels in CYP3A7*1C carriers compared with non-carriers.
cMissing values: 2-OHE2, 1 sample (non-carrier); 2-MeOE2, 11 samples (11 women, 2 non-carriers, 9 carriers); 3-MeOE1, 11 samples (9 women, 2 non-carriers, 7 carriers), 16-ketoE2, 5 samples (3
women, 2 non-carriers, 1 carrier).
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Strengths of our study include our comprehensive analysis of
urinary EMs using HPLC-MS/MS and, as genotypes are effectively
randomised at birth (Ebrahim and Davey Smith, 2008), our focus on
a genetic variant (the CYP3A7*1C allele), which minimises the
potential for confounding by unmeasured environmental factors.
There are several limitations to our study; owing to the frequency of
the CYP3A7*1C allele, the numbers are small and, given our
selection procedure, the non-carriers may not be representative of
the White British population. Our choice of using two consecutive
periovulatory samples makes it difficult to compare EM levels in our
study with other published reports, which have mainly analysed a
single luteal phase sample (Eliassen et al, 2009, 2012; Faupel-Badger
et al, 2010; Maskarinec et al, 2012). In addition, we do not have
prospective data on CYP3A7*1C carrier status, hormone levels and
breast cancer risk in large numbers of women, and we cannot
compare breast cancer risk in women with low levels of the parent
oestrogen E1 according to their CYP3A7*1C status (and hence 2-
hydroxylation:16a-hydroxylation ratio) directly.
In conclusion, we have demonstrated that the CYP3A7*1C allele
has a profound effect on levels of the parent oestrogen E1 and the
ratio of 2-hydroxylation:16a-hydroxylation EMs in premenopausal
women. To characterise the association between parent oestrogens,
EMs and subsequent risk of breast cancer fully, identification of
additional genetic variants that influence parent oestrogens and
particular pathway EMs, and further prospective studies that
analyse a broad spectrum of EMs will be required.
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